Navigation Links
Inverness Medical Innovations Agrees to Acquire 'Second Territory' Rapid Diagnostics Business of ACON
Date:3/19/2009

lts for calendar year 2008, as well working capital and other customary adjustments. Inverness does not presently intend to obtain financing from outside sources for this acquisition. Instead, Inverness expects to self-finance the transaction from cash on hand and its ongoing cash flows, and has the ability to pay a portion (up to approximately 34%) of the purchase price in shares of Inverness common stock valued as of the date that the shares are issued. The purchase price will be paid in a series of payments, the first to occur at Closing and the last to occur in October 2011.

Ron Zwanziger, Chief Executive Officer of Inverness, stated: "We have been very pleased with our first acquisition from ACON in 2006. Our initial success combined with our ongoing business relationship with ACON made the decision to proceed with the Second Territory an easy one. ACON's 2008 revenues for this business were approximately $45 million at attractive operating margins. We are very pleased to have entered into this agreement, particularly when considering today's worldwide economic challenges, and similar to the 2006 acquisition, we are confident that this transaction will prove beneficial to employees, customers, ACON, Inverness and its investors."

About Inverness Medical Innovations

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life at home. Inverness' global leading products and services, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts.

For more information about Inverness Medical Innovations, please visit our website at '/>"/>

SOURCE Inverness Medical Innovations, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Inverness Completes Acquisition of Cholestech
2. Inverness Medical Innovations Acquires Bio-Stat Healthcare Group
3. Inverness Medical Innovations Acquires Alere Medical
4. Inverness Medical Innovations Announces Closing of Public Offering
5. Inverness Medical Innovations to Participate at 2007 RBC Healthcare Conference on December 12, 2007
6. Inverness Medical Innovations to Acquire Redwood Toxicology Laboratory
7. Inverness Medical Innovations Enters Into a Definitive Agreement to Acquire Matria Healthcare, Inc.
8. Inverness Medical Innovations to Present at 2008 UBS Global Healthcare Services Conference on February 13, 2008
9. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET February 20, 2008 to Discuss Fourth Quarter 2007 Results
10. Law Offices of Howard G. Smith Announces Investigation on Behalf of Current and Former Employees of Inverness Medical Innovations, Inc. Who Invested in the Inverness Medical Innovations, Inc. Employee Savings Plan
11. Correction: Law Offices of Howard G. Smith Announces Investigation on Behalf of Shareholders of Inverness Medical Innovations, Inc.

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...ption leads to success, study finds , ,...rcise, reduced soda consumption and self-weighing ...gies for adolescents, a new study shows. , Rese...t-control strategies and lifestyle habits. Sixty-t...The responses were grouped into four categories: ,...
(Date:12/4/2009)...patient groups , , FRIDAY, Dec. 4 (Healt... Ewing sarcomas and central nervous system tumors,...rs have found. , The study authors analyzed dat...on pediatric cancers who were enrolled in the Chil...found that the overall cancer recurrence rate was ...
(Date:12/4/2009)... to take breast cancer drug, study finds , ...out side effects are a major reason why only 6 per...cer are willing to take the drug tamoxifen to prev...ort to inform women about the risks and benefits o...igan Comprehensive Cancer Center created a decisio...
(Date:12/4/2009)...4 Today, seven of Florida,s top no...ng the health of Florida,s uninsured and underserv...2009 Sapphire Award ceremony. ,, The Sapphire A...izes and promotes organizations that have demonstr...ithin their communities. ,, Honorees of The 200...
(Date:12/4/2009)...re-FirstCall/ -- Movado Group Inc. (NYSE: MOV ),...a, Georgia, shared in a tribute on December 3, 200...ie Oudin for her stellar performance in the tourna...finalist at the Open since 1999. ,, (Photo: ...84 ) ,, At a celebratory reception held at Brow...
Breaking Medicine News(10 mins):Health News:Teens Lose More Weight Using Healthy Strategies 2Health News:High-Risk Women May Often Avoid Using Tamoxifen 2Health News:Top Nonprofits Honored for Improving Health of Floridians 2Health News:Top Nonprofits Honored for Improving Health of Floridians 3
... May 20, 2009Physicians can and should play a lead...g towards comprehensive reform of the way health c...uaranteed 1.5 percent annual savings in health car...chieving Health Care ReformHow Physicians Can Help...
...al communities in California,s Central Valley , ,...re, one of the nation,s first and leading provider...of nephrology research, today announced their part...e Park in the City of Stockton. Satellite Healthca...
...ostatic intraepithelial neoplasia (HGPIN) carries ...ostate cancer. Research published in the open acce...atients whose extended core biopsy led to an initi...dation Trust and Lancaster University, along with ...
...hareholders to Support the Company,s Twelve Nomine..., Inc. (Nasdaq: AMLN ) today reminded its shareh...l of Amylin,s nominees, including its two new inde...bourne Capital Management, L.L.C. , , Amylin,s 20...
...., May 26 Cogdell Spencer Inc. (NYSE: CSA ) ann...lic offering of 18,000,000 shares of common stock....ters an option to purchase up to an additional 2,7...eds from the offering to fund a $50 million repaym...
...6 , , About Dr. Harold Kohn & Vimpat , A...l compound that affects neurological systems, Haro...hapel Hill , inventor of the recently FDA-approved... of perseverance, and Veronica was thrilled to tha...
Other Medicine News:Health News:Physicians can lead health care reform through payment and delivery system reforms 2Health News:Satellite Healthcare Walks for Kidney Health 2Health News:Amylin Advises All Shareholders to Vote Their Blue Proxy Card Today 2Health News:Amylin Advises All Shareholders to Vote Their Blue Proxy Card Today 3Health News:Amylin Advises All Shareholders to Vote Their Blue Proxy Card Today 4Health News:Cogdell Spencer Announces Commencement of Common Stock Offering 2Health News:Cogdell Spencer Announces Commencement of Common Stock Offering 3Health News:Inventor of Newly Available Vimpat(R) (lacosamide) C-V Meets a Woman Who Experienced Greater Seizure Control With Use of This New Antiepileptic Drug 2Health News:Inventor of Newly Available Vimpat(R) (lacosamide) C-V Meets a Woman Who Experienced Greater Seizure Control With Use of This New Antiepileptic Drug 3
(Date:12/4/2009)... 4 Chemistry World re... Pharmaceutical Research and Manufacturers of Ame...accines in development for HIV/AIDS and related co...products in development include 23 vaccines and 54...cal trials or awaiting approval by the U.S. Food a...
(Date:12/4/2009)...wire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: ...ntermeasures against biological and chemical threa... results of a study demonstrating the effectivenes... in the New Zealand White (NZW) rabbit. The data ...HHS Public Health Emergency Medical Countermeasure...
(Date:12/4/2009)...4 OrthoAccel Technologies, Inc., d...acceleration device to enhance orthodontics, annou...n course published by PennWell Corporation , a le..., including medicine and dentistry. The course fo..., a summary of treatment biomechanics, factors tha...
Breaking Medicine Technology:U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4DURECT Corporation to Participate in Upcoming Healthcare Conferences 57474 1DURECT Corporation to Participate in Upcoming Healthcare Conferences 57474 2National Survey Reveals Healthcare Providers Technological Readiness to Participate in Electronic Health Records Network 57469 1National Survey Reveals Healthcare Providers Technological Readiness to Participate in Electronic Health Records Network 57469 2National Survey Reveals Healthcare Providers Technological Readiness to Participate in Electronic Health Records Network 57469 3YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 14116 1YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 14116 2YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 14116 3YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 14116 4
... a First-in-Class Biologic Treatment Option Now Av...s with JIA(1,2) -, PRINCETON, N.J., April 8, 2008... announced that the U.S. Food and Drug,Administrat...reducing signs,and symptoms in pediatric patients ...tive polyarticular juvenile idiopathic arthritis (...
...d., April 8, 2008 ImQuest scientists Robert,W. Bu...nted the results of,studies performed with product...ecent Microbicides 2008, an international conferen...icide scientists, developers, and care,givers from...ak by the,Conference organizers, presenting the re...
Other Medicine Technology:U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 2U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 3U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 4U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 5U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 6U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 7U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 8U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 9U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 10ImQuest Scientists Present Important HIV Microbicide Development Results at Microbicides 2008 in Delhi, India 2
Goat Anti-Human IgA, alpha chain Antibody, Colloidal Gold Conjugated, 50 OD
Protein A 50 OD, Colloidal Gold Conjugated/Tagged
Protein A, Gold Ribbon - .25 OD per sq. cm.
Protein G, Gold Ribbon - .50 OD per sq. cm.
Medicine Products: